Abstract
Background
AML blast populations are heterogeneous in their phenotype and functional properties, and contain a small subset of cells that regenerate leukemia in immunocompromised mice or produce clonogenic progeny in long-term cultures. This suggests the existence of a hierarchy of AML progenitor cells. CD33 is a myeloid marker absent on normal hematopoietic stem cells but expressed in about 75% of AML patients, and has been used for BM purging strategies and Ab-targeted therapies. These CD33 Ab therapies benefit only a minority of AML patients, suggesting that AML stem cells are heterogeneous in their CD33 expression.
Methods
In order to evaluate this question, we determined expression levels of CD34 and CD33 on AML progenitors with long-term in vitro proliferative ability and NOD/SCID engrafting ability.
Results
The CD34+ CD33− subfraction contained the majority of progenitors detected in vitro and most often engrafted the mice. This proliferation was leukemic from the CD34+ AML patients, however from the CD34− AML patients only normal progenitors were detected in this fraction in some cases.
Discussion
These data suggest that most leukemic progenitors of CD34+ patients do not express CD33. In contrast, CD34− AML primitive leukemic progenitors may be CD33+. CD34− AML patients could potentially benefit most from CD33-targeted therapies or purging.